Forxiga receives positive EU CHMP opinion
1 February 2019 1:15pm GMT Forxiga receives positive EU CHMP opinionfor the treatment of adults with type-1 diabetes Forxiga is the first oral medicine recommended for approval in Europeas an adjunct treatment to insulin for adults with type-1 diabetes The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxiga (dapagliflozin), after adopting a positive opinion for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D). Forxiga, a